🚨 #ESMO26 的 KRAS G12C NSCLC 重磅结果！
III 期 Krascendo 1（N=338）：divarasib 对比 sotorasib/adagrasib。
OS：17.7 对比 12.0 个月
HR 0.56（95% CI 0.41–0.78）
PFS：9.8 对比 5.7 个月
HR 0.58（0.44–0.76）
一项重要的随机对照生存期进展。#LCSM
Krascendo 1 的更多结果：
47 浏览 · 2 赞 · 0 转发 · 2 回复
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org- gilberto lopes@GlopesMd
Next: CNS efficacy, resistance, sequencing and moving KRAS inhibition earlier. Skoulidis et al. NEJM 2026.
- gilberto lopes@GlopesMd
ORR: 58.4% vs 32.3% DOR: 11.9 vs 6.9 mo Serious TRAEs: 7.8% vs 15.2% TRAEs leading to discontinuation: 4.8% vs 11.7% Caveats: few adagrasib-treated patients, untreated brain metastases excluded, limited follow-up. Divarasib remains investigational.
来源：gilberto lopes · x.com